[Waldenström macroglobulinaemia]

Cécile Tomowiak; Stéphanie Poulain; Céline Debiais; Stéphanie Guidez; Xavier Leleu

doi:10.1016/j.lpm.2019.07.020

[Waldenström macroglobulinaemia]

Presse Med. 2019 Jul-Aug;48(7-8 Pt 1):832-841. doi: 10.1016/j.lpm.2019.07.020. Epub 2019 Aug 20.

[Article in French]

Authors

Cécile Tomowiak¹, Stéphanie Poulain², Céline Debiais³, Stéphanie Guidez¹, Xavier Leleu⁴

Affiliations

¹ CHU de Poitiers, service d'oncohématologie et thérapie cellulaire, 86021 Poitiers.
² CHU de Lille, laboratoire d'hématologie cellulaire, 59000 Lille.
³ CHU de Poitiers, laboratoire d'anatomie cytologie pathologiques, 86021 Poitiers.
⁴ CHU de Poitiers, service d'oncohématologie et thérapie cellulaire, 86021 Poitiers. Electronic address: xavier.leleu@chu-poitiers.fr.

PMID: 31444019
DOI: 10.1016/j.lpm.2019.07.020

Abstract

Lymphoplasmocytic lymphona with monoclonal lgM, rare. Median age at diagnosis 70 years old, frail population. Heterogenous clinic presentation. Molecular diagnosis with MYD88. Treatment required for symptomatic WM patients only. 1st line therapy: DRC. Input of targeted therapies (ibrutinib) for frail patients, maintenance effect.

Publication types

Review

MeSH terms

Adenine / analogs & derivatives
Age of Onset
Aged
DNA Mutational Analysis / methods
Frail Elderly
Humans
Molecular Diagnostic Techniques / methods
Molecular Targeted Therapy / methods
Molecular Targeted Therapy / trends
Myeloid Differentiation Factor 88 / genetics
Piperidines
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Waldenstrom Macroglobulinemia* / diagnosis
Waldenstrom Macroglobulinemia* / epidemiology
Waldenstrom Macroglobulinemia* / genetics
Waldenstrom Macroglobulinemia* / therapy

Substances

MYD88 protein, human
Myeloid Differentiation Factor 88
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine